Archive for September, 2011

Senate Appropriation Activities (NSF, NIH) … and now House Activity

Update: Jocelyn Kaiser notes that the House appropriations committee draft bill for Labor, HHS, and Education gives the NIH a 3.3% increase (!!) over FY11 funding levels while maintaining funding for NCRR (including $100M boost in its IDeA program) and not incorporating NCATS or CAN (but allowing $2M in the OD to go toward planning). Stay tuned as the sausage continues to be made.

The Senate Committee on Appropriations has spoken on FY12 proposals for commerce & justice and science (including NSF) and labor, health & human services, and education (including NIH).

Last week, the Committee reduced the NSF’s appropriation by $162M (2.4% cut from FY11), which would reduce funding for NSF’s 6 research directorates by $120M, to $5.44B, and spending on education by $32M, to $829M. The Committee’s proposal gives the NSF the flexibility to move up to $100M from other pots into the facilities budget (maintained at $224M), which will likely happen to maintain progress on various NSF initiatives. The House bill would maintain NSF’s overall budget at 2011 levels but shrink the facilities account to $100M.

The NIH fared no better in Committee, which cut their appropriation by $190M to $30.5B. The Senate bill also provides for the creation of NCATS (including $20M for CAN), which the National Review opined amounts to Obama Pharmaceuticals, Inc., and the elimination of NCRR. The House never got its act together on its corresponding appropriations bill. Could be worse. Could be raining.

Actually, while a cut of any size to the NIH budget is unprecedented, it could indeed be worse, given the current fiscal climate, and Rep. Rosa DeLauro (D-Conn) makes a nice plug for research funding (especially the need for consistency and continuity) in The Hill, so the NIH does still have vocal advocates among the ranks. About now would be a good time to let your Congressional delegation know the importance of maintaining research funding levels – at least steady if the appropriation cannot be increased.

Neither the full House nor the Senate has voted on any appropriations bills, though the House just rejected the proposed CR, which would have funded the federal government through Nov 18th at 1.5% below FY11 levels. Once again, a federal shut-down looms. Could be worse. Could be …

Update: Boehner strong-armed conservatives into approving essentially the same CR, which the Senate rejected.

Comments (7)

NCRR Offline?

Hopefully only its Web server, as the Center’s URL is not accessible with various browsers (including linked from the NIH homepage) …

You are not authorized to view this page
You do not have permission to view this directory or page due to the access control list (ACL) that is configured for this resource on the Web server.
——————————————————————————–

and its cached page is a few hours old:

This is Google’s cache of http://www.ncrr.nih.gov/. It is a snapshot of the page as it appeared on Sep 20, 2011 17:38:46 GMT.

No doubt temporary, but what are the chances that the Website of just this IC would go down?

Update: Not long after this post went up, so did the NCRR Website. Coincidence?

Comments (6)

Collins on Slippery Slope to NCATS

To hear Collins and the White House talk about it, you would think NCATS was a done deal.

In fact, it has already committed $70M to a joint project with DARPA and the FDA to “develop cutting-edge technologies to predict drug safety” as mentioned in a White House news release associated with the signing of the America Invents Act:

NCATS aims to help biomedical entrepreneurs by identifying barriers to progress and providing science-based solutions to reduce costs and the time required to develop new drugs and diagnostics. For example, as one of its initial activities, NCATS will partner with DARPA to support development of a chip to screen for safe and effective drugs far more swiftly and efficiently than current methods.

It seems, based on the NIH news release, that things will happen quickly:

This fall, the two agencies, in coordination with FDA, will solicit proposals from industry, government labs, academic institutions, and other research organizations on how best to develop the chip, bringing together the latest advances in engineering, biology, and toxicology to bear on this complex problem.

Interesting order in the listing of anticipated applicants.

Fortunately, the job announcement soliciting applications for Director of NCATS includes such expertise as a prerequisite:

The Director, NCATS, will provide visionary leadership, executive management, and strategic direction for streamlining the process for therapeutics development. … The Director, NCATS, will identify ways to leverage existing NIH resources to speed the delivery of new, more effective medical products to patients.

Just 3 months ago, Collins was told by Congress not to search for a Director for a Center that had not yet been approved. NCATS does not appear in the CR, which mandates an across the board 1.409% cut to FY11 appropriation levels (through Nov 18th), and no other indication of likely approval has been issued from the House or Senate.

This is a neat trick for Collins to commit $70M in funds – likely from the Common Fund – to a project affiliated with a Center that does not exist. Review of applications for NCATS’s inaugural Director start December 2nd. At least s/he knows there will be a $70M project waiting to be supervised. Whether there will be a Congressionally approved Center outside the OD is another story.

Comments (5)

Follow

Get every new post delivered to your Inbox.

Join 114 other followers